Abnormal
aggregation of the microtubule-associated protein tau
into intracellular fibrillary inclusions is characterized as the hallmark
of tauopathies, including Alzheimer’s disease and chronic traumatic
encephalopathy. The hexapeptide 306VQIVYK311 (PHF6) of R3 plays an important role in the aggregation of tau.
Recent experimental studies reported that phosphorylation of residue
tyrosine 310 (Y310) could decrease the propensity of PHF6 to form
fibrils and inhibit tau aggregation. However, the underlying inhibitory
mechanism is not well understood. In this work, we systematically
investigated the influences of phosphorylation on the conformational
ensembles and oligomerization dynamics of PHF6 by performing extensive
all-atom molecular dynamics (MD) simulations. Our replica exchange
MD simulations demonstrate that Y310 phosphorylation could effectively
suppress the formation of β-structure and shift PHF6 oligomers
toward coil-rich aggregates. The interaction analyses show that hydrogen
bonding and hydrophobic interactions among PHF6 peptides, as well
as Y310–Y310 π–π stacking and I308–Y310
CH−π interactions, are weakened by phosphorylation. Additional
microsecond MD simulations show that Y310 phosphorylation could inhibit
the oligomerization of PHF6 by preventing the formation of large β-sheet
oligomers and multi-layer β-sheet aggregates. This study provides
mechanistic insights into the phosphorylation-inhibited tau aggregation,
which may be helpful for the in-depth understanding of the pathogenesis
of tauopathies.